Navegar

Colección

Datos Estadísticas

Artículo

Mallea-Gil, M.S.; Cristina, C.; Perez-Millan, M.I.; Villafañe, A.M.R.; Ballarino, C.; Stalldecker, G.; Becu-Villalobos, D. "Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers" (2009) Endocrine Pathology. 20(1):35-40
Estamos trabajando para incorporar este artículo al repositorio
Consulte el artículo en la página del editor
Consulte la política de Acceso Abierto del editor

Abstract:

The present study reports the case of a 70-year-old Caucasian man who was referred to the Military Hospital of Buenos Aires for evaluation of a giant sellar-extrasellar mass with extension in the right temporal lobe and compression of the third ventricle. Patient was initially responsive to cabergoline with reduction of prolactin levels and shrinkage of tumor burden for at least 36 months. Thereafter, prolactin levels and tumor size increased even though cabergoline dosage was increased. Transcraneal surgery was performed at 56 months of treatment. Prolactin levels and tumor proliferation did not subside and the patient died 14 months later. High GH and IGF-I levels were observed in the late stages of tumor development, with no evidence of acromegalic features. Immunohisto-chemistry of the excised tumor revealed strong immunore-activity for VEGF and FGF-2, two potent angiogenic factors, and CD31 (an endothelial marker) indicating high vascularization of the adenoma. © Humana Press Inc. 2009.

Registro:

Documento: Artículo
Título:Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers
Autor:Mallea-Gil, M.S.; Cristina, C.; Perez-Millan, M.I.; Villafañe, A.M.R.; Ballarino, C.; Stalldecker, G.; Becu-Villalobos, D.
Filiación:Hospital Militar Central, Luis Maria Campos 726, Ciudad Autónoma, Buenos Aires 1426, Argentina
Instituto de Biología y Medicina Experimental, CONICET, Ciudad Autónoma, Vuelta de Obligado 2490, Buenos Aires 1428, Argentina
Hospital General de Agudos Pirovano, Ciudad Autónoma, Monroe 3555, Buenos Aires, Argentina
Palabras clave:Dopamine agonist resistance; FGF; IGFI; Ki67; Prolactinoma; VEGF; cabergoline; CD31 antigen; fibroblast growth factor 2; growth hormone; Ki 67 antigen; octreotide; somatomedin C; vasculotropin; antineoplastic agent; cabergoline; ergoline derivative; prolactin; tumor marker; aged; amnesia; article; attention disturbance; brain third ventricle; cancer invasion; case report; drug dose increase; fatality; gait disorder; growth hormone release; headache; human; immunohistochemistry; male; priority journal; prolactinoma; sleep disorder; temporal lobe; tumor growth; tumor vascularization; visual impairment; blood; drug resistance; genetics; hypophysis tumor; hypothyroidism; metabolism; neovascularization (pathology); nuclear magnetic resonance imaging; pathology; prolactinoma; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Ergolines; Humans; Hypothyroidism; Immunohistochemistry; Magnetic Resonance Imaging; Male; Neovascularization, Pathologic; Pituitary Neoplasms; Prolactin; Prolactinoma; Tumor Markers, Biological
Año:2009
Volumen:20
Número:1
Página de inicio:35
Página de fin:40
DOI: http://dx.doi.org/10.1007/s12022-009-9057-3
Título revista:Endocrine Pathology
Título revista abreviado:Endocr. Pathol.
ISSN:10463976
CODEN:ENPAF
CAS:cabergoline, 81409-90-7; growth hormone, 36992-73-1, 37267-05-3, 66419-50-9, 9002-72-6; octreotide, 83150-76-9; somatomedin C, 67763-96-6; vasculotropin, 127464-60-2; prolactin, 12585-34-1, 50647-00-2, 9002-62-4; Antineoplastic Agents; Ergolines; Prolactin, 9002-62-4; Tumor Markers, Biological; cabergoline, 81409-90-7
Registro:https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_10463976_v20_n1_p35_MalleaGil

Referencias:

  • Corsello, S.M., Ubertini, G., Altomare, M., Lovicu, R.M., Migneco, M.G., Rota, C.A., Colosimo, C., Giant prolactinomas in men: Efficacy of cabergoline treatment (2003) Clinical Endocrinology, 58 (5), pp. 662-670. , DOI 10.1046/j.1365-2265.2003.01770.x
  • Lundin, P., Pedersen, F., Volume of pituitary macroadenomas: Assessment by MRI (1992) J Comput Assist Tomogr, 16, pp. 519-528. , doi:10.1097/00004728-199207000-00004
  • Molitch, M.E., Pharmacologic resistance in prolactinoma patients (2005) Pituitary, 8 (1), pp. 43-52. , DOI 10.1007/s11102-005-5085-2, Special Issie on Pathogenesis, Diagnosis and Clinics of Prolactinomas
  • Pernicone, P.J., Scheithauer, B.W., Sebo, T.J., Kovacs, K.T., Horvath, E., Young Jr., W.F., Lloyd, R.V., Schoene, W.C., Pituitary carcinoma: A clinicopathologic study of 15 cases (1997) Cancer, 79 (4), pp. 804-812. , DOI 10.1002/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2- 3
  • Delgrange, E., Crabbe, J., Donckier, J., Late development of resistance to bromocriptine in a patient with macroprolactinoma (1998) Hormone Research, 49 (5), pp. 250-253. , DOI 10.1159/000023180
  • McCall, D., Hunter, S.J., Cooke, R.S., Herron, B., Sheridan, B., Atkinson, A.B., Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma [2] (2007) Clinical Endocrinology, 66 (1), pp. 149-150. , DOI 10.1111/j.1365-2265.2006.02686.x
  • Turner, H.E., Nagy, Zs., Gatter, K.C., Esiri, M.M., Harris, A.L., Wass, J.A.H., Angiogenesis in pituitary adenomas - Relationship to endocrine function, treatment and outcome (2000) Journal of Endocrinology, 165 (2), pp. 475-481
  • Mucha, S.A., Melen-Mucha, G., Godlewski, A., Stepien, H., Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat (2007) Virchows Archiv, 450 (3), pp. 335-341. , DOI 10.1007/s00428-006-0351-x
  • Pawlikowski, M., Grochal, M., Kulig, A., Zielinski, K., Stepien, H., Kunert-Radek, J., Mucha, S., The effect of angiotensin II receptor antagonists on diethylstilbestrol- induced vascular changes in the rat anterior pituitary gland: A quantitative evaluation (1996) Histology and Histopathology, 11 (4), pp. 909-913
  • Stepien, H., Grochal, M., Zielinski, K.W., Mucha, S., Kunert-Radek, J., Kulig, A., Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fischer 344 rats (1996) J Endocrinol, 150, pp. 99-106. , doi:10.1677/joe.0.1500099
  • Gorczyca, W., Hardy, J., Microadenomas of the human pituitary and their vascularization (1988) Neurosurgery, 22, pp. 1-6. , doi:10.1097/ 00006123-198801010-198900001
  • De La Torre, N.G., Wass, J.A., Turner, H.E., Morphologic changes and molecular regulation of angiogenesis in pituitary adenomas (2004) Front Horm Res, 32, pp. 133-145. , doi:10.1159/000079042
  • Ferrara, N., Davis-Smyth, T., The biology of vascular endothelial growth factor (1997) Endocrine Reviews, 18 (1), pp. 4-25. , DOI 10.1210/er.18.1.4
  • Bikfalvi, A., Klein, S., Pintucci, G., Rifkin, D.B., Biological roles of fibroblast growth factor-2 (1997) Endocrine Reviews, 18 (1), pp. 26-45. , DOI 10.1210/er.18.1.26
  • Komorowski, J., Jankewicz, J., Stepien, H., Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of pituitary tumours (2000) Cytobios, 101, pp. 151-159
  • Cristina, C., Diaz-Torga, G., Gongora, A., Guida, M.C., Perez-Millan, M.I., Baldi, A., Fibroblast Growth Factor-2 in hyperplastic pituitaries of D2R knockout female mice (2007) Am J Physiol Endocrinol Metab, 293, pp. E1341-E1351. , doi:10.1152/ ajpendo.00260.2007
  • Cristina, C., Diaz-Torga, G., Baldi, A., Gongora, A., Rubinstein, M., Low, M.J., Becu-Villalobos, D., Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice (2005) Endocrinology, 146 (7), pp. 2952-2962. , http://endo.endojournals.org/cgi/reprint/146/7/2952, DOI 10.1210/en.2004-1445
  • Kim, K., Yoshida, D., Teramoto, A., Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas (2005) Endocrine Pathology, 16 (2), pp. 115-121. , DOI 10.1385/EP:16:2:115
  • Minematsu, T., Suzuki, M., Sanno, N., Takekoshi, S., Teramoto, A., Osamura, R.Y., PTTG overexpression is correlated with angiogenesis in human pituitary adenomas (2006) Endocrine Pathology, 17 (2), pp. 143-153. , DOI 10.1385/EP:17:2:143, PII EP172143
  • Piroli, G., Torres, A., Grillo, C., Lux-Lantos, V., Aoki, A., De Nicola, A.F., Mechanisms in progestin antagonism of pituitary tumorigenesis (1998) J Steroid Biochem Mol Biol, 64, pp. 59-67. , doi:10.1016/ S0960-0760(97)00139-148
  • Brue, T., Pellegrini, I., Priou, A., Morange, I., Jaquet, P., Prolactinomas and resistance to dopamine agonists (1992) Horm Res, 38, pp. 84-89
  • Delgrange, E., Trouillas, J., Maiter, D., Donckier, J., Tourniaire, J., Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study (1997) Journal of Clinical Endocrinology and Metabolism, 82 (7), pp. 2102-2107. , DOI 10.1210/jc.82.7.2102
  • Maraschini, C., Moro, M., Masala, A., Toja, P., Alagna, S., Brunani, A., Chronic treatment with parlodel LAR of patients with prolactin-secreting tumours. Different responsiveness of microand macroprolactinomas (1991) Acta Endocrinol (Copenhagen), 125, pp. 494-501
  • Caccavelli, L., Morange-Ramos, I., Kordon, C., Jaquet, P., Enjalbert, A., Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas (1996) J Neuroendocrinol, 8, pp. 737-746. , doi:10.1046/j.1365-2826.1996.04902.x
  • Caccavelli, L., Feron, F., Morange, I., Rouer, E., Benarous, R., Dewailly, D., Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas (1994) Neuroendocrinology, 60, pp. 314-322. , doi:10.1159/000126764
  • Ferrara, N., Gerber, H.-P., LeCouter, J., The biology of VEGF and its receptors (2003) Nature Medicine, 9 (6), pp. 669-676. , DOI 10.1038/nm0603-669
  • Schechter, J., Goldsmith, P., Wilson, C., Weiner, R., Morphological evidence for the presence of arteries in human prolactinomas (1988) J Clin Endocrinol Metab, 67, pp. 713-719
  • Jugenburg, M., Kovacs, K., Stefaneanu, L., Scheithauer, B.W., Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: A quantitative morphologic study (1995) Endocr Pathol, 6, pp. 115-124. , doi:10.1007/BF02739874
  • Lloyd, R.V., Scheithauer, B.W., Kuroki, T., Vidal, S., Kovacs, K., Stefaneanu, L., Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas (1999) Endocr Pathol, 10, pp. 229-235. , doi:10.1007/BF02738884
  • McCabe, C.J., Boelaert, K., Tannahill, L.A., Heaney, A.P., Stratford, A.L., Khaira, J.S., Vascular endothelial growth factor, its receptor KDR/ Flk-1, and pituitary tumor transforming gene in pituitary tumors (2002) J Clin Endocrinol Metab, 87, pp. 4238-4244. , doi:10.1210/jc.2002-020309
  • Arita, K., Kurisu, K., Tominaga, A., Sugiyama, K., Eguchi, K., Hama, S., Relationship between intratumoral hemorrhage and overexpression of vascular endothelial growth factor (VEGF) in pituitary adenoma (2004) Hiroshima J Med Sci, 53, pp. 23-27
  • Basu, S., Nagy, J.A., Pal, S., Vasile, E., Eckelhoefer, I.A., Bliss, V.S., Manseau, E.J., Mukhopadhyay, D., The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor (2001) Nature Medicine, 7 (5), pp. 569-574. , DOI 10.1038/87895
  • Chakroborty, D., Sarkar, C., Mitra, R.B., Banerjee, S., Dasgupta, P.S., Basu, S., Depleted dopamine in gastric cancer tissues: Dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis (2004) Clin Cancer Res, 10, pp. 4349-4356. , doi:10.1158/1078-0432. CCR-04-0059
  • Cristina, C., Garcia-Tornadu, I., Diaz-Torga, G., Rubinstein, M., Low, M.J., Becu-Villalobos, D., Dopaminergic D2 receptor knockout mouse: An animal model of prolactinoma (2006) Frontiers of Hormone Research, 35, pp. 50-63. , DOI 10.1159/000094308, Pituitary Today: Molecular, Physiological and Clinical Aspects
  • Gaffey, T.A., Scheithauer, B.W., Lloyd, R.V., Burger, P.C., Robbins, P., Fereidooni, F., Corticotroph carcinoma of the pituitary: A clinicopathological study. Report of four cases (2002) J Neurosurg, 96, pp. 352-360
  • Gurlek, A., Karavitaki, N., Ansorge, O., Wass, J.A.H., What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics (2007) European Journal of Endocrinology, 156 (2), pp. 143-153. , DOI 10.1530/eje.1.02339
  • Oliveira, M.C., Marroni, C.P., Pizarro, C.B., Pereira-Lima, J.F., Barbosa- Coutinho, L.M., Ferreira, N.P., Expression of p53 protein in pituitary adenomas (2002) Braz J Med Biol Res, 35, pp. 561-565

Citas:

---------- APA ----------
Mallea-Gil, M.S., Cristina, C., Perez-Millan, M.I., Villafañe, A.M.R., Ballarino, C., Stalldecker, G. & Becu-Villalobos, D. (2009) . Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers. Endocrine Pathology, 20(1), 35-40.
http://dx.doi.org/10.1007/s12022-009-9057-3
---------- CHICAGO ----------
Mallea-Gil, M.S., Cristina, C., Perez-Millan, M.I., Villafañe, A.M.R., Ballarino, C., Stalldecker, G., et al. "Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers" . Endocrine Pathology 20, no. 1 (2009) : 35-40.
http://dx.doi.org/10.1007/s12022-009-9057-3
---------- MLA ----------
Mallea-Gil, M.S., Cristina, C., Perez-Millan, M.I., Villafañe, A.M.R., Ballarino, C., Stalldecker, G., et al. "Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers" . Endocrine Pathology, vol. 20, no. 1, 2009, pp. 35-40.
http://dx.doi.org/10.1007/s12022-009-9057-3
---------- VANCOUVER ----------
Mallea-Gil, M.S., Cristina, C., Perez-Millan, M.I., Villafañe, A.M.R., Ballarino, C., Stalldecker, G., et al. Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers. Endocr. Pathol. 2009;20(1):35-40.
http://dx.doi.org/10.1007/s12022-009-9057-3